UPDATE: Goldman Sachs Lowers Johnson & Johnson's PT

Loading...
Loading...
According to a research report published earlier today, Goldman Sachs has lowered Johnson & Johnson's
JNJ
PT from $70 to $65. Goldman Sachs commented in the report, “With JNJ's earnings recovery story clouded by continued challenges in its Consumer and MD&D business, and potential competition to Zytiga and Incivo, we see the stock's premium valuation tested.” Goldman Sachs maintains its Neutral rating on Johnson & Johnson, which is currently trading at $63.34.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsGoldman Sachs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...